Payment overview · 2025
General Payments
$1,054.03
18 reported records · 6 companies
Healthcare provider profile · identity verified
Madeline Cherubin, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OAKLAND PARK, FL · NPI 1629436985
Verified facts
What the public records show
CMS Open Payments records show Madeline Cherubin, ARNP received $1,054.03 in general payments during 2025 across 18 reported records.
Gilead Sciences, Inc. accounted for 38.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Eliquis, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Biktarvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $405.03 | 38.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $345.78 | 32.8% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $222.97 | 21.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.68 | 3.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.11 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.46 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,054.03 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $373.96 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $345.78 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $222.97 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.11 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 19 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 36 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 362 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 155 |
| Lisinopril | Lisinopril | 175 | 78 |
| Metformin Hcl | Metformin Hcl | 148 | 73 |
| Omeprazole | Omeprazole | 144 | 76 |
| Losartan Potassium | Losartan Potassium | 134 | 61 |
| Gabapentin | Gabapentin | 124 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 57 |
| Glipizide | Glipizide | 110 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 44 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 90 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 42 |
| Nifedipine Er | Nifedipine | 80 | 40 |
| Jardiance | Empagliflozin | 75 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 71 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 29 |
| Furosemide | Furosemide | 54 | 21 |
| Latanoprost | Latanoprost | 53 | 25 |
| Carvedilol | Carvedilol | 48 | 25 |
| Simvastatin | Simvastatin | 48 | 24 |
| Mirtazapine | Mirtazapine | 46 | 23 |
| Azithromycin | Azithromycin | 43 | 38 |
| Famotidine | Famotidine | 43 | 18 |
| Spironolactone | Spironolactone | 42 | 22 |
| Atenolol | Atenolol | 41 | 13 |
| Cephalexin | Cephalexin | 41 | 37 |
| Clonidine Hcl | Clonidine Hcl | 41 | 19 |
| Amoxicillin | Amoxicillin | 40 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 24 |
| Januvia | Sitagliptin Phosphate | 37 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 18 |
| Meloxicam | Meloxicam | 33 | 25 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | 12 |
| Alendronate Sodium | Alendronate Sodium | 30 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 16 |
| Mupirocin | Mupirocin | 29 | 18 |
| Baclofen | Baclofen | 27 | 18 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 22 |
| Tradjenta | Linagliptin | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 15 |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 15 |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Ozempic | Semaglutide | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Eliquis | Apixaban | 19 | 14 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | 11 |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nystatin | Nystatin | 16 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Fluconazole | Fluconazole | 15 | 12 |
| Bumetanide | Bumetanide | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Naproxen | Naproxen | 14 | 11 |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,054.03 · 18 records | Gilead Sciences, Inc. | ABRYSVO, AIRSUPRA, Biktarvy, COMIRNATY, Cologuard Collection Kit, ELIQUIS, JARDIANCE, NURTEC ODT, PREVNAR 20 | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error